Alefacept: Clinical Trials

5 trials of Alefacept, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated. 5 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Completed 3, Terminated 2
Phase 21Completed 1

Follow Alefacept: new trials by email Literature Review of Alefacept trials Research Report on Alefacept

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Alefacept in Patients With Relapsed/Refractory Aplastic Anemia
Alefacept - Aplastic Anemia
Phase 1TerminatedThe Cleveland Clinic42011-05-012018-01-26
A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Alefacept (ASP0485) - Transplant; Failure, Kidney
Phase 1TerminatedNorthwestern University92010-07-012013-05-03
A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers
alefacept, placebo - Pharmacokinetics of Alefacept
Phase 1CompletedAstellas Pharma Inc752008-03-012013-02-28
Alefacept for Chronic Graft Versus Host Disease
Alefacept - Resistant Chronic GVHD
Phase 1 / Phase 2CompletedHadassah Medical Organization202006-10-012015-04-21
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
Alefacept - Lymphoma
Phase 1CompletedMayo Clinic232006-03-012019-08-13

Conditions studied

Anemia, Aplastic (1)  ·  Immunoblastic Lymphadenopathy (1)  ·  Lymphoma (1)  ·  Lymphoma, Extranodal NK-T-Cell (1)  ·  Lymphoma, Large-Cell, Anaplastic (1)  ·  Lymphoma, T-Cell, Cutaneous (1)  ·  Mycosis Fungoides (1)  ·  Sezary Syndrome (1)

Sponsors

Astellas Pharma Inc (1)  ·  Hadassah Medical Organization (1)  ·  Mayo Clinic (1)  ·  Northwestern University (1)  ·  The Cleveland Clinic (1)

Countries

United States (4)  ·  Israel (1)

Top investigators

M. Javeed Ansari, MD (1)  ·  Michael Y Shapira, MD (1)  ·  Ramon V. Tiu, M.D. (1)  ·  Thomas E. Witzig, MD (1)

NIH funding

P30CA015083 (1), P50CA097274 (1)